Embed Size (px)
Citation preview
La Physique Médicale demain: Perspectives en Radiothérapie
A.Mazal, P.Francois, N.Fournier-Bidoz, R.Belshi
M. Dutreix, S. Heinrich, C. Wessels, A.Fourquet
Service de Physique Médicale Dept de Radiothérapie Oncologique Institut Curie, France
Remerciements: J-C.Rosenwald, P.Lambin (Maastro), D.Verellen, T.Lomax, G.Olivera, D.Galmarini ………… France-Hadron, Areva, Cancéropôle
!"#$%&'()%*'$%+,"%+-'((.'(-+(/01234#'(5&.36+-'()%2,*#*(7#$3'8(9(:";'<=$'(>?@A(
!"#$%&'%(
)*+'"%,&-(
./#01#2*3(4%(0#(4*+%(
BC#*$'2D(
B)<+E'$3'D(
BF"23<&*$3'D(
G#,-2(B+#*"<+,4#'2D(
7"<<'(BH;+-#+,"%D('%(5'.(/012I(
Menu du jour :
1) Physique et technologie : vers la radiothérapie Adaptative
2) Besoin d’ouverture en R&D : vers la Biologie
3) Divers, discussion et conclusions
La Physique Médicale demain: Perspectives en Radiothérapie Externe
J"<"*0&$+K3'(
LLLM61='$N%3O'M6"<(P+K3.C$6("#('4#3;+-'%*'2(QLK0"2K3*+-2M"$ER(
S'$"( S3'LP+1(Q5P)TA7"UV?(LW5X7(
56-+'71%(%,(,%863*0*$'%(Y(X'2(212*Z<'2(K$"K"2&2(+6*#'--'<'%*('%(PJ('[*'$%'((
1 Beam 5 Beams 11 Beams
17 Beams 25 Beams 51 Beams
mm mm mm
mm mm mm
QO$"<(J"<"*0'$+K1R(
X+(<#-,K-363*&(.\3%63.'%6'2((WW(X'($]-'(.'(-\H%'$E3'(
9:;<=*+%3>#04(
/0"*"%2(H-'6*$"%2( /$"*"%2W)"%2(
^"_L+$'Y(S+$3+%`2(H6-3K2'(WW(a'+<(F+*+(Y()aC(WW(7+-62(Y(CM5+b+-U()M7#$3'( c(
/$"*"%2(
?@A/*012*3(,%863*0*$'71%(%3(6#4&*3,6A&#B'%(
P"=",4#'(.'(K"23,"%%'<'%*((
5+603%'2(K-#2(6"<K+6*'2(
a$+2(32"6'%*$34#'2(
7$1"E&%3'( C66&-'$+*'#$(+(K+$"3(.3'-'6*$34#'( C66'-&$+,"%(X+2'$(
C#4&*3,6%&#B-(D(56-+'8#0(+%0%82/',-((#34E*&((=#4'*F'*0*$'8#0(%G%8,+(
* pions * fast & slow neutrons * protons * light and heavy ions Raju & Koehler, 1980
IMXT
Linear Energy Transfer
(Past)
(Present)
(Future ?)
(
P+.3+,"%(a3"-"E1Y(
(
F"2'(.32*$3=#,"%(3%((
%+%"<'*'$(26+-'(
5M(d$+'<'$(
F"2'U'e'6*U$'-+,"%203K(
Schulz-Ertner, IJROBP 2007
Conventional RT
Protons
C-Ions
BoS chondrosarcomas
C#(*"K(.'(-+(21E<"3.'(.'(6"%*$]-'(-"6+-(ff(
F+$<2*+.*(g(h'3.'-='$E(H[(2+$6"<'2(.'(-+(=+2'(.#(6$i%'(
;*3H*&"( !I=J( J*"*(=#B'4(K&8( 5&*,L( 5&*,M( 5&*,N( 5&*,(
5#,86(
((
OV-( P(
5CPJPQR( CK)=PQR(
S(( ((L(( ((((((T ((((((M (((((((N((((((((U ((((((((V(( ((((((((W(( ((((((((X (((SY(
X3%+6S+$3+%(>@??7^H( J"<"*0'$+K1(hF( )aC(K$"*"%*0'$+K1(212*'<(
)*+'"%,&'8(8*"B#&'+*3+D((+-+,%"+(#/#'0#F0%(#,(!3+2,1,(;1&'%(
!I=J(Z[%4(/+(
=#B'4K&8(
!I=J(
=#B'4(K&8(
!I=J(
=#B'4(K&8(
!"#$
%&'(()*$
+),-./$
0)'&-12$
OV-:!SLN(
=#B'4K&8(5(
5(
K(
K(
)*+%(\]-^(
)'+,#38%(\8"^(
)*+%(,*(H%"*�(6%#4(\]-^((D(=#2*+(/+(OV-,6%&#B-(
_*&(S<N(]-(`"#[a($'/%3(F-(OV-(,*(,6%(H%"*�(6%#4+b((#00(,6%(*,6%&+(,%863'71%+(4%0'/%&(SY(,*(NY(]-b(+*((#(*(*H(V(,*(TY(2"%+(6'$6%&(
Y(
SY(
LY(
TY(
MY(
NY(
UY(
^12*Z<'2(.'(K-+%3j6+,"%(Y()5PJ8(kF(
(()<+E'$3'(<#-,<".+-3*&(Y(7"$$'-+,"%(.\3<+E'28(G#,-2(.'(6"%*"#$+E'(
H%(6"#$2(.\3%*$".#6,"%Y(Bl+2*((d%"L-'.E'(=+2'.(/-+%%3%ED(
X\&;"-#,"%(.'2("#,-2(-"E32,4#'2(Y((
(The Tree of Imaging in Radiation Therapy) Creteil, EPU G.Marinello 3'4',15$6"),5/'$,.*7'&789((
IGRT : Image Guided Radiation Therapy
IRM MVCT kV&Fluo/gantry kV&fluo fixed
Video Surface
Vision/ Laser
Echo
TREATMENT
PACS CTSim
TPS
Simul-RT FUSION
PR
EPA
RAT
ION
CT IRM PET-CT GammaCamera Mammo Radio Echo DIAGNOSTIC
CBCT
MVPortal PET_CT & gamma
PACS CTSim
Simul-RT FUSION
PR
EPA
RAT
ION
CT IRM PET-CT GammaCamera Mammo Radio Echo DIAGNOSTIC
PET_CT & gamma
IRM kV fixe
Video Surface
Vision/ Laser
TREATMENT
CBCT kVPortal
MVPortal
Tomo-MVCT
Echo
7. Dose delivered per image
TPS
0
0
0
0
0
0.1-1 mGy
0.1-1 mGy
0.1-1 mGy
0.1-1 mGy
Fluo
10-70 mGy x 2
10-30 mGy
5-50 mGy
5-50 mGy 5-50 mGy
1-50 mSv
10-30 mGy
56-+'71%("A4'8#0%(4%"#'3D(5%&+B%82/%+(%3(=#4'*,6A&#B'%(
U(!""#$%&'()*+$,-$.)(($/#"0&12$/""#$%&'()*+$1()3)1'($"&*1"42$
5)#6$72#2((238$$9#&::2(:8$92(;)&4$
U(m'(%''.(*"(B2''D(*0'(*#<"$8(*0'(<36$"U'%;3$"%<'%*((+%.(*"(<:22$"&#$:1'(/2(=$
U m'(3220$*"$#202:);3$*>2$?@$/#"12::A$+%.(*"(K'$O"$<(+(/#"12::$"#)23*20$#):6$'3'(+:):M((
56-+'71%("A4'8#0%(4%"#'3D(5%&+B%82/%+(%3(=#4'*,6A&#B'%((
5)#6$72#2((238$$9#&::2(:8$92(;)&4$BCDCE$
U(m'(%''.(+66#$+*'($'K"$*2("O(*0'$'1*&'($02()F2#20$0":2$+*('+60(O$+6,"%(I8((
U(G#$(K$3"$3*1(32(GH-$*>2$02F2("/423*$"I$32.$J2'4:$'30$32.$I'31+$4'1>)32:$
U(m'(%''.(E"".(0'*'$4)3)3;$*""(:$O$"<(.3e'$'%*(0"2K3*+-2(
U(J0'%(L'(<3E0*(2*+$*(*"(#%.'$2*+%.(*0'(#'0)"J)"(";+$"I$*>2$*&4"#$'30$>2'(*>+$K::&2:8(I(
).'+2(O"$(5'.36+-(/012362(3%(*0'(O#*#$'(J"%1(X"<+[8(^L3*b'$-+%.(
((
• C#*"<+*'.8($32N(<3%3<32'.(+%.(,<'('n63'%*(oC(
• F+3-1(C.+K*'.(J$'+*<'%*2(Q$'+-U,<'R(()%U;3;"(."2'W$+%E'(;'$3j6+,"%2W$'6"%2*$#6,"%2(
(• a3"-"E36+-(+22'22<'%*(=+2'.("%(+66#$+*'(
*$'+*<'%*(."2'(.32*$3=#,"%2W$'6"%2*$#6,"%2((• l$"<(5+6$"(*"(<36$"(Y(6'--#-+$(-';'-(
/-+%%3%E()<+E3%E(J$'+*<'%*(/-+%%3%E(
C.+K,;'(Y(*0'(L"$Np"L(
H-'6*$"%36(/$'26$3K,"%(
qM(G-3;'$+(FMq+-<+$3%3(r^C(
/-+%%3%E()<+E3%E(J$'+*<'%*(/-+%%3%E(
J0'(L"$Np"L(
H-'6*$"%36(/$'26$3K,"%(
>F(s(AF()%($""<()<+E3%E(
/-+%%3%E()<+E3%E(J$'+*<'%*(/-+%%3%E(
J0'(L"$Np"L(
H-'6*$"%36(/$'26$3K,"%(
)%($""<()<+E3%E( )<+E'(P'E32*$+,"%(+%.(K+,'%*(2'*#K(
J$'+*<'%*(F'-3;'$1(
/-+%%3%E()<+E3%E(J$'+*<'%*(/-+%%3%E(
J0'(L"$Np"L(
H-'6*$"%36(/$'26$3K,"%(
)%($""<()<+E3%E( )<+E'(P'E32*$+,"%(+%.(K+,'%*(2'*#K(
J$'+*<'%*(F'-3;'$1(
J$'+*<'%*(C22'22<'%*(
f(
/-+%%3%E()<+E3%E(J$'+*<'%*(/-+%%3%E(
J0'(L"$Np"L(
H-'6*$"%36(/$'26$3K,"%(
)%($""<()<+E3%E( )<+E'(P'E32*$+,"%(+%.(K+,'%*(2'*#K(
J$'+*<'%*(F'-3;'$1(
J$'+*<'%*(C22'22<'%*(
f(K4#B,(J&%#,"%3,(
c(
7-++2(m'22'-28(/0F(2*#.'%*8()M7#$3'(
)%6'$,*#.'2('%(%--'2(*'60%34#'2Y($"*+,"%%'--'2('*(K$"*"%2(
5&*"B,(]#""#(
d%3O'U'.E'(2-3*(6+<'$+(
_<=*%00'3$6*G<((56)b(!OK<((
(5*+',&*3(."'++'*3(J*"*$&#B6-(H&*"(B#2%3,(#82/#2*3(>',6(,6%(F%#"(
mM(H%E0+$.*('*(+-(
(S<(d%(6#/%(#0"*+,(B0#,%#1%4(*1,('3(,6%(4*+%(8*3H*&"#2*3(B&*F0%"(`SYY(-%#&+a((((L<(PB2"'e#2*3(*H(4*+%(4%0'/%&-(*/%&(2"%(`6-B*:HR*3#2*3bfab(F'*0*$'8#0(,#&$%23$b(((((8*"F'3%4("*4#0'2%+(`86%"*:=Jab<<<<((T<(;*+,:%G%82/%3%++('3(6%#0,68#&%(`86%#B%&(,&%#,"%3,+a(((
( ( (!(&%+%#&86('3(I%4'8#0(56-+'8+g(
G%'(3.'+W;323"%("%(K012362((3%($+.3+,"%(*0'$+K1(*"<"$$"Lf((J6*"#+(O*&h%04b(O*+,*3b(iRK(
)5PJ( /$"*"%(
Proton dose escalation still spares more normal tissues Proton 87.5 GY vs photon 60 GY in stage I Proton 74 GY vs photon 60 Gy in stage III (Chang et al: Int J Rad Onc Bio Phys 65:1087-96, 2006)
Stage III
LUNG 5MFMC%.'$2"%8(h"#2*"%8(r^C(
/03-3KK'(X+<=3%8(5++2*$"8(a'-E3#<(
X3%E('*(+-(
/HJ(q#3.'.((P+.3"*0'$+K1(
Drug Uptake 89Zirconium – Cetuximab
C'$*2('*(+-(
S+%(H-<K*('*(+-(
m''N(>(F#$3%E(PJ(
« Cold spot »:
Less Drug Uptake
(GTVLDU)
“W-Effect”"Ponette et al. (2000) Int J Radiat Biol 76: 1233-43 - Fernet et al. Int J Radiat Biol 76: 1621-29!
Early cell response to split-dose irradiation"
^#$;3;3%E(O$+6,"
%(
P+.3"2'%
23,;3*1(
UHDR, pulse irradiation to reduce the complications of radiotherapy - U612 Meeting - Orsay, 5-6 sept. 2011"
S3%6'%*((l+;+#."%(
=j)(
.G%,(4#3+(0%(,%"B+f(
t"-+%.+(/$'b+."8(l$+%6'(Y('e'*(.+%2(-\'2K+6'(
!"#$%&'()&*+,'&)-.&'/0%-10(0&%/23-4,)-!3-5,-6-7898(*-!:;#
!"#$%&''(")$%*+$'&+'"#,-.$*/$&0"1%234&56"7.."($0/8*"('*'(9':6 !"#$%&'(#$)*"'+*%';<=>?;@ABC;D<E;F<GGG68/'8+(6%(0
!"#$%#&'"(#&))" $*+," +#&" ),-&'"(#&))."/#$("0',1&(("'&)&!(&("
&*&'%2"+20$1!))2"+#',3%#"43'+#&'"&)&1+',*"&5$(($,*"!*6"!("
&!1#"&5$++&6"&)&1+',*")&!6("+,"+#&"1'&!+$,*",4"!*"!66$+$,*!)"
7!1!*128" +#$("0',1&(("1!*"1!(1!6&" )&!6$*%"+,"+#&"&5$(($,*"
,4"!")!'%&"*359&'",4"(&1,*6!'2"&)&1+',*(:"0,(($9)2"!("5!*2"
!(";<"$*"+#&"1!(&",4"!*"$**&'=(#&))"$,*$(!+$,*"$*"%,)6.">3%&'"
&)&1+',*("!'&"+20$1!))2"7&'2"),-"&*&'%2"?@A"B&CD"!*6"(#,'+"
'!*%&8"5&!*$*%"+#&2"6&0,($+"7&'2"#$%#"6,(&("$*"+#&"7$1$*$+2"
!"#$%&'"E355!'2",4"&F0&'$5&*+!)"0!'!5&+&'("4,'"$*7&(+$%!+$,*("6&5,*(+'!+$*%"+#&"'!6$,(&*($+$G$*%"0',0&'+$&(",4"HIJ("!"#$!%&'
Author Size (nm) Concentration Surface coating Cell model Source energy Observed SE~
Butterworth et al. (30) 1.9 2.4 µM Thiol DU-145 160 kVp <1
0.24 µM MDA231MB <1.67
AG0-1522 <1.97
Astro <1.04
L132 <1
T98G <1.91
MCF-7 <1.41
PC-3 <1.07
Chang et al. (31) 13 11 µM Citrate B16F10 6 MV e- 1
Chien et al. (32) 20 <2 mM Citrate CT-26 6 MV 1.19
Chithrani et al. (33) 14 1 µM Citrate HeLa 220 kVp 1.17-1.6
74 6 MV e-
50 662 keV
Coulter et al. (34) 1.9 12 µM Thiol DU-145 160 kVp <1.8
MDA-231MB
L132
Geng et al. (35) 14 5 µM Glu! SK-OV-3 90 kVp 1.3
6 MV 1.2
Jain et al. (36) 1.9 12 µM Thiol DU-145 160 kVp <1.41
MDA-231MB 6 MV <1.29
L132 15 MV 1.16
6 MeV e- <1.12
16 MeV e- 1.35
Kong et al. (37) 10.8 15 nM Glu! MCF-7 200 kVp 1.3
AET MCF-10A 662 keV 1.6
1.2 MV
Lui et al. (38) 6.1 >1 mM PEG CT-26 6 keV 2
EMT-6 160 kVp 1.1
6 MV 1
Rahman et al. (39) 1.9 <1 mM Thiol BAEC 80 kV 20
150 kV 1.4
6 MV e- 2.9
12 MV e- 3.7
Roa et al. (40) 10.8 15 nM Glu! DU-145 662 keV >1.5
Zhang et al. (41) 30 15 nM Glu! DU-145 200 kVp >1.3
!thioglucose; cysteamine; polyethyleneglycol; ~Sensitizer enhancement defined as the level of radiosensitization observed when comparing cells irradiated in the presence of GNPs to control exposures
)%(;3*$"(
)%(;3;"(
q"-.(%+%"K+$,6-'2(a#u'$L"$*0('*(+-(J$+%2-+*(7+%6'$(P'28(>?@A(((
r,-32+,"%(.'2(:+%"K+$,6#-'2(K"#$(+<&-3"$'$(-'2(K'$O"$<+%6'2(.'(-+(
h+.$"%*0&$+K3'(
.&'k#(5P=;.?(!3+2,1,(4%+(R8'%38%+(I*0A810#'&%+(4@P&+#-((
^"#*'%+%6'(.'(*0Z2'(F3$'6,"%(Y(^M(XC7G5aH(
5"L+*('*(+-(
/-+,%'(q+."-3%'#<(
P'<3*+('*(+-(
(l+3.(a"2*"%(G6*(>??V(U(
v(h+.$"%*0'$+K1(w(O"$(+(K0123632*f(
Q.HW.[Rx(k(!(b'e>('k(:CyWC(<';>((z(-%(Q><;>W("(Q@U#>RR(U(#(>(U($Q73WyR({(((% 0 = 14.1 z / p v { sqrt ( L / LR) ( 1+ log(L /LR ) / 9 ) }((
q.v.B = mv2/r
C66'-'$+*"$2( a'+<(*$+%2K"$*( +%.(.'-3;'$1(
5'+2#$'<'%*2( <".'-2((g(*$+3*'<'%*(
5#-,.3263K-3%+$3*&(Y(='2"3%(.\#%(-+%E+E'(6"<<#%(((
v(h+.$"%*0'$+K1(w((O"$(*0'(K012363+%(
LYST(
(l(?#(B6-+'71%("A4'8#0%(4%"#'3D(B%&+B%82/%+(%3('*,6A&#B'%(m((n1%(4%(0#(O'*0*$'%((
(?%+(,%863'71%+(%,(0%+('3+,&1"%3,+(*3,(B&*$&%++A(B01+(/',%(71%(3*,&%(8*33#'++#38%(4%+(%G%,+(71%(8%+(&#-*3+('341'+%3,(+1&(0%(/'/#3,((
(P+.3"*0&$+K3'(6"%O"$<+,"%'--'(((P+.3+,"%(+;'6(<".#-+,"%(.\3%*'%23*&(((((Q)5PJR('*(+$6(*0&$+K3'(;"-#<&*$34#'(QS5CJR(
((
r%'(."23<Z*$3'((5#-,U&60'--'((>F((AF((kF((f(
(?@'3,A$*3(4%(0#(56-+'71%(%,(4%(0#(O'*0*$'%D(13%(&A/*012*3(o(/%3'&g((
501+'%1&+86#00%3$%+(0'A+(#1[(3*1/%#1[(H#'+8%#1[((U(-'2(<36$"U('*(<3%3UO+326'+#[((U(-'2(#-*$+0+#*2(.&=3*2(.'(."2'(Q3$$+.3+,"%2(K#-2&'2R((U(-\0+.$"%*0&$+K3'((U(-'2(K-+2<+2IM(
501+'%1&+(86#00%3$%+(0'A+(#1[(8*"F'3#'+*3+((U(%+%"K+$,6#-'2(|('e'*(+<K-3j6+*'#$(.'2($+1"%2((U(*0&$+K3'2(63=-&'2(Q3%03=3*'#$2(.'(-\+%E3"E&%Z2'8(.'(-+($&K+$+,"%8(.#(616-'IR(
TISSU SAIN &TISSU TUMORAL , QUELLE DOSE?
DOSE apparente?
SXNY( 5+$3'(F#*$'3[(
H}/HP)5H:JCX(PCF)GJhHPC/t(lC7)X)Jt(
l$'.'$36(/"#b"#-'*( ^"K03'(h'3%$360(
Conclusions 1) Physique et technologie :
vers la radiothérapie Adaptative avec optimisation du flux
2) Besoin d’ouverture en R&D : par ex vers la Biologie
La Physique Médicale demain: Perspectives en Radiothérapie Externe
!"#$%(( ( (!]=J(56-+'8+ ( (5]=J((O'*0*$-( ( (O]=J(.8*3*"'8#0( (.;=J(ff<<(
;0'3'8#0( ( ( (;]=J(
R*8'#0( ( ( ( (R]=J(
From Bill Chu, PTCOG 50, USA k~(( ( ( (I%&8'((g(
